Literature DB >> 27343020

Adult-Onset Hypogonadism.

Mohit Khera1, Gregory A Broderick2, Culley C Carson3, Adrian S Dobs4, Martha M Faraday5, Irwin Goldstein6, Lawrence S Hakim7, Wayne J G Hellstrom8, Ravi Kacker9, Tobias S Köhler10, Jesse N Mills11, Martin Miner12, Hossein Sadeghi-Nejad13, Allen D Seftel14, Ira D Sharlip15, Stephen J Winters16, Arthur L Burnett17.   

Abstract

In August 2015, an expert colloquium commissioned by the Sexual Medicine Society of North America (SMSNA) convened in Washington, DC, to discuss the common clinical scenario of men who present with low testosterone (T) and associated signs and symptoms accompanied by low or normal gonadotropin levels. This syndrome is not classical primary (testicular failure) or secondary (pituitary or hypothalamic failure) hypogonadism because it may have elements of both presentations. The panel designated this syndrome adult-onset hypogonadism (AOH) because it occurs commonly in middle-age and older men. The SMSNA is a not-for-profit society established in 1994 to promote, encourage, and support the highest standards of practice, research, education, and ethics in the study of human sexual function and dysfunction. The panel consisted of 17 experts in men's health, sexual medicine, urology, endocrinology, and methodology. Participants declared potential conflicts of interest and were SMSNA members and nonmembers. The panel deliberated regarding a diagnostic process to document signs and symptoms of AOH, the rationale for T therapy, and a monitoring protocol for T-treated patients. The evaluation and management of hypogonadal syndromes have been addressed in recent publications (ie, the Endocrine Society, the American Urological Association, and the International Society for Sexual Medicine). The primary purpose of this document was to support health care professionals in the development of a deeper understanding of AOH, particularly in how it differs from classical primary and secondary hypogonadism, and to provide a conceptual framework to guide its diagnosis, treatment, and follow-up.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27343020     DOI: 10.1016/j.mayocp.2016.04.022

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  21 in total

Review 1.  Endocrinological aspects of HIV infection.

Authors:  F S Mirza; P Luthra; L Chirch
Journal:  J Endocrinol Invest       Date:  2018-01-08       Impact factor: 4.256

Review 2.  Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age.

Authors:  Alexander W Pastuszak; Marc Gittelman; James P Tursi; Jonathan S Jaffe; David Schofield; Martin M Miner
Journal:  Andrology       Date:  2021-10-08       Impact factor: 4.456

3.  Age ≤40 is an independent predictor of anastomotic urethroplasty and successful repair of bulbar urethral strictures.

Authors:  Michael T Davenport; Jeffrey T Wooliscroft; Maxim J McKibben; Nabeel Shakir; Joceline S Fuchs; Yooni A Yi; Boyd R Viers; Rachel L Bergeson; Ellen E Ward; Allen F Morey
Journal:  Transl Androl Urol       Date:  2020-02

4.  Is opioid use safe in women trying to conceive?

Authors:  Kerry S Flannagan; Sunni L Mumford; Lindsey A Sjaarda; Jeannie G Radoc; Neil J Perkins; Victoria C Andriessen; Jessica R Zolton; Robert M Silver; Enrique F Schisterman
Journal:  Epidemiology       Date:  2020-11       Impact factor: 4.860

Review 5.  Adult-onset hypogonadism: evaluation and role of testosterone replacement therapy.

Authors:  Andrew J Davidiuk; Gregory A Broderick
Journal:  Transl Androl Urol       Date:  2016-12

6.  Impact of recent FDA ruling on testosterone replacement therapy (TRT).

Authors:  Sarita O Metzger; Arthur L Burnett
Journal:  Transl Androl Urol       Date:  2016-12

Review 7.  Testosterone replacement therapy and the heart: friend, foe or bystander?

Authors:  David S Lopez; Steven Canfield; Run Wang
Journal:  Transl Androl Urol       Date:  2016-12

8.  Treatment of Estrogen Levels in the Management of Hypogonadism: An Anonymous Survey of ISSM Members.

Authors:  Mohit Butaney; Nannan Thirumavalavan; Adithya Balasubramanian; J Abram McBride; Jabez Gondokusumo; Alexander W Pastuszak; Larry I Lipshultz
Journal:  Urology       Date:  2020-02-08       Impact factor: 2.649

Review 9.  Late-onset hypogonadism: Clinical evidence, biological aspects and evolutionary considerations.

Authors:  Nikolai Jaschke; Andrew Wang; Lorenz C Hofbauer; Martina Rauner; Tilman D Rachner
Journal:  Ageing Res Rev       Date:  2021-02-18       Impact factor: 10.895

Review 10.  Endogenous and exogenous testosterone and prostate cancer: decreased-, increased- or null-risk?

Authors:  David S Lopez; Shailesh Advani; Konstantinos K Tsilidis; Run Wang; Steven Canfield
Journal:  Transl Androl Urol       Date:  2017-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.